Citi Maintains a Buy Rating on Eli Lilly and Company (LLY), Retains the $1,190 PT

Eli Lilly and Company (NYSE:LLY) is one of the best drug stocks to buy right now. Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) on September 10, retaining the price target of $1,190.00. Was Jim Cramer Right About Eli Lilly and Company (LLY)? The analyst supported the optimistic outlook with the promising outlook for the company’s obesity treatment, tirzepatide, stating that the treatment attained the highest cost-effectiveness rating in the recent draft report by ...